Category Press Releases

Corazon

Corazon, Columbia HeartSource Introduce First-of-Its-Kind Open-Heart Surgery Accreditation

Corazon and Columbia HeartSource Announce Partnership Offering First-of-its-Kind Open-Heart Surgery Accreditation Columbia HeartSource, an extension of Columbia University Irving Medical Center’s Department of Surgery and Division of Cardiology and Corazon, a national leader in strategic program development for cardiovascular services, today…

Read MoreCorazon, Columbia HeartSource Introduce First-of-Its-Kind Open-Heart Surgery Accreditation
Atlas

Atlas Oncology Partners Secures $28M Series A Funding to Expand Value-Based Cancer Care

Atlas Oncology Partners Raises $28M Series A to Scale Value-Based Oncology Care Atlas Oncology Partners today announced the closing of its Series A financing. Atlas was founded by Rubicon Founders, a healthcare investment firm focused on building and growing companies…

Read MoreAtlas Oncology Partners Secures $28M Series A Funding to Expand Value-Based Cancer Care
NashBio

NashBio Announces Leadership Appointments to Advance Technology and Real-World Data Access

NashBio Announces Key Leadership Roles, Advancing Technological Enablement and Access to Real-World Data Nashville Biosciences LLC a leading real-world, multi-omics data company, today announced the appointment of Wacey Richards to Chief Technology Officer (CTO) and Elizabeth Ann Stringer to Chief…

Read MoreNashBio Announces Leadership Appointments to Advance Technology and Real-World Data Access
HemoSonics’

HemoSonics’ Quantra System Selected as 2026 Edison Awards Finalist for Obstetric Care

HemoSonics’ Quantra Hemostasis System for Obstetric Procedures Named a 2026 Edison Awards Finalist HemoSonics LLC, a medical device company focused on acute bleeding management, today announced that its Quantra® Hemostasis System for Obstetric Procedures is one of the top three finalists in the Women’s…

Read MoreHemoSonics’ Quantra System Selected as 2026 Edison Awards Finalist for Obstetric Care
NextPoint

NextPoint Therapeutics Announces Clinical Debut of Novel NPX372 for Solid Tumor Treatment

NextPoint Therapeutics Announces Clinical Entry of NPX372, a First-in-Class B7-H7–Targeted T Cell Engager to Treat Solid Tumors NextPoint Therapeutics, a clinical-stage biotechnology company developing a new world of precision therapeutics through its leading scientific work on the novel B7-H7 axis,…

Read MoreNextPoint Therapeutics Announces Clinical Debut of Novel NPX372 for Solid Tumor Treatment
Nuvation

Nuvation Bio Launches Global Phase 3 SIGMA Trial of Safusidenib for IDH1-Mutant Glioma

Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma Nuvation Bio Inc. a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced finalization of a protocol amendment to…

Read MoreNuvation Bio Launches Global Phase 3 SIGMA Trial of Safusidenib for IDH1-Mutant Glioma
Ethris

Ethris and DZIF Form Strategic Partnership to Advance Development of mRNA-Based Vaccines

Ethris and German Center for Infection Research (DZIF) Announce Strategic Collaboration to Develop mRNA-Based Vaccines Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, and the German Center for Infection Research (Deutsches Zentrum für Infektionsforschung, DZIF), today announced…

Read MoreEthris and DZIF Form Strategic Partnership to Advance Development of mRNA-Based Vaccines
Fenebrutinib

Fenebrutinib by Genentech Marks Major Breakthrough in Treating Primary Progressive Multiple Sclerosis

Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS) Genentech, a member of the Roche Group announced today new late-breaking data from the Phase III FENtrepid study showing…

Read MoreFenebrutinib by Genentech Marks Major Breakthrough in Treating Primary Progressive Multiple Sclerosis

Roche’s Fenebrutinib Shows First PPMS Disability Reduction in Over a Decade

Roche’s fenebrutinib becomes the first investigational therapy in over a decade to slow disability progression in primary progressive multiple sclerosis (PPMS) Roche announced today new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton’s tyrosine kinase (BTK)…

Read MoreRoche’s Fenebrutinib Shows First PPMS Disability Reduction in Over a Decade
Atlas

Morgan Stanley and the American Heart Association Unite for the 17th Go Red Women’s Leadership Event

Morgan Stanley to Host 17th Annual Go Red Women’s Leadership Event in Collaboration with the American Heart Association In special recognition of the Go Red for Women® campaign, Morgan Stanley Wealth Management will collaborate with the American Heart Association in Westchester…

Read MoreMorgan Stanley and the American Heart Association Unite for the 17th Go Red Women’s Leadership Event
Press Ganey

Press Ganey and Compass Healthcare Publish New e-Book on the Future of Compassionate Care

Press Ganey and Compass Healthcare Launch New e-Book: Intelligence with Empathy: Building the future of compassionate care Press Ganey, an experience measurement provider to over 41,000 healthcare organizations, and Compass Healthcare, a leading provider of healthcare support services for hospitals and health systems,…

Read MorePress Ganey and Compass Healthcare Publish New e-Book on the Future of Compassionate Care